March 03, 2017
RemedyRepack Inc has issued a voluntary recall of 630 Glipizide 2.5 mg extended-release (ER) tablets, according to the latest US Food and Drug Administration (FDA) Enforcdement Report.
Glipizide ER tablets are used, along with diet and exercise, in patients with type 2 diabetes to improve glycemic control.
Semaglutide Shows Promise in Type 2 Diabetes
Continuous Glucose Monitoring Continues to Show Promise: Studies
The FDA classified the recall as Class II on February 18, 2017—“a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
The lot number of the affected products is B0129373-021916, Exp. 10/17. The FDA report lists the original NDC as 00591-0900-30 and the RemedyRepack NDC as 52125-0764-02.
The recall was initiated on February 7, 2017. It is currently in progress.
The recalled tablets were manufactured by Watson Laboratories, Inc, and repackaged by RemedyRepack.
-Meredith Edwards White